Prophylactic cranial irradiation after reaching complete response, partial response, or stable disease in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (ProACT).
Amanda Tufman
Honoraria - Roche
Other Remuneration - AstraZeneca; Roche
Claus Belka
Honoraria - AstraZeneca; Roche
Other Remuneration - AstraZeneca; Roche
Heike Kuenzel
No relevant relationships to disclose
Rudolf M. Huber
Consultant or Advisory Role - Roche
Honoraria - AstraZeneca; Roche
Other Remuneration - AstraZeneca (I); Roche